Mesoblast (NASDAQ:MESO) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Mesoblast (NASDAQ:MESO) in a research report report published on Thursday, Benzinga reports.

Several other equities analysts have also recently weighed in on MESO. StockNews.com raised Mesoblast from a sell rating to a hold rating in a research note on Tuesday. Piper Sandler upgraded Mesoblast from a neutral rating to an overweight rating and upped their price target for the stock from $4.00 to $11.00 in a report on Tuesday, July 23rd. Finally, Jefferies Financial Group upgraded Mesoblast from a hold rating to a buy rating in a report on Thursday.

Mesoblast Stock Up 1.6 %

NASDAQ:MESO opened at $6.47 on Thursday. The business’s 50-day moving average price is $6.85 and its 200 day moving average price is $5.78. The firm has a market cap of $738.73 million, a P/E ratio of -5.78 and a beta of 3.48. Mesoblast has a 52-week low of $1.61 and a 52-week high of $8.66.

Institutional Trading of Mesoblast

Several large investors have recently made changes to their positions in the business. Marshall Wace LLP bought a new stake in shares of Mesoblast during the second quarter worth $562,000. Chase Investment Counsel Corp bought a new stake in shares of Mesoblast during the first quarter worth $298,000. XTX Topco Ltd bought a new stake in shares of Mesoblast during the second quarter worth $103,000. Chapin Davis Inc. grew its holdings in shares of Mesoblast by 50.0% during the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock worth $102,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Rathbones Group PLC bought a new stake in shares of Mesoblast during the second quarter worth $95,000. Institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.